Loss of TGF-β inhibition and increased TGF-β signaling have been associated with cancer progression, stemness, therapeutic resistance as well as immune suppression.41 Several TGF-β targeting agents are being examined in breast cancer. This evidence concerns the gene TGFB1 and breast carcinoma.